We invested in Suven Pharma in December 2019 (pre-demerger) at a price of Rs 131 a share (adjusted for the demerger of Suven Life Sciences). Over the last four years, the stock has zoomed to Rs 1,000 implying a 7.6 bagger (663% return) for us in one of the highest quality pharma business of CDMO run by an incredible owner-operator.

We remained invested in this exceptional business even when the promoter changed from Mr Jasti to a private equity player in Dec’22, as we found the stated strategy of making Suven a platform interesting. The ongoing merger of Cohance, along with few other smaller acquisitions, does seem to indicate prompt steps toward the stated goal.

Even though most of the acquisitions are believed to be EPS accretive and hence could create value for shareholders of Suven Pharma, it does seem to be priced-in to a great extent at the current market cap of Rs 25,500 Cr for a business that currently does about Rs 1,000 Cr in annual sales & Rs 400-500 Cr in net profit.

If Advent (PE) executes well with proper integration of these acquired assets and extracts the maximum synergies out of this platform, there could be further optionalities/upside that may emerge over time implying we could be missing out on those. But based on the current available information, we believe the risk-reward doesn’t seem to be favorable to carry this position any further. When we invested at Rs 131, we had very little to lose but a lot to gain making risk-reward very favourable for us, today at Rs 1,000 it is the exact opposite. Keeping in mind the same, we recently exited this investment.

We consider ourselves to be in the profession of primarily managing the risks and not the returns. This essentially implies the returns are only ‘optimised’ as opposed to being ‘maximised’, while trying to minimise the risks that can lead to permanent loss of capital. Further, any attempt to consistently buy at the bottom or sell at the top is only theoretical and doesn’t work in real life.

—

Check out the two services offered by Stalwart via the links shared below:

1. Portfolio Management Service (For HNIs): Click here to see the Presentation
2. Fundamental Equity Research (Model Portfolio for DIY): Click here to read more

—

Disclaimer: This is not a recommendation to buy/hold/sell. Please consult your financial advisor before acting on it. Read the complete disclaimer here.